Poly [ADP Ribose] Polymerase 1 (ADP Ribosyltransferase Diphtheria Toxin Like 1 or NAD(+) ADP Ribosyltransferase 1 or Poly[ADP Ribose] Synthase 1 or PARP1 or EC 2.4.2.30) - Pipeline Review, H2 2017

Published: Oct, 2017 | Pages: 145 | Publisher: Global Markets Direct
Industry: Pharmaceuticals & Healthcare | Report Format: Electronic (PDF)

Poly [ADP Ribose] Polymerase 1 (ADP Ribosyltransferase Diphtheria Toxin Like 1 or NAD(+) ADP Ribosyltransferase 1 or Poly[ADP Ribose] Synthase 1 or PARP1 or EC 2.4.2.30) - Pipeline Review, H2 2017

Summary

Poly [ADP Ribose] Polymerase 1 (ADP Ribosyltransferase Diphtheria Toxin Like 1 or NAD(+) ADP Ribosyltransferase 1 or Poly[ADP Ribose] Synthase 1 or PARP1 or EC 2.4.2.30) pipeline Target constitutes close to 31 molecules. Out of which approximately 27 molecules are developed by companies and remaining by the universities/institutes. The latest report Poly [ADP Ribose] Polymerase 1 - Pipeline Review, H2 2017, outlays comprehensive information on the Poly [ADP Ribose] Polymerase 1 (ADP Ribosyltransferase Diphtheria Toxin Like 1 or NAD(+) ADP Ribosyltransferase 1 or Poly[ADP Ribose] Synthase 1 or PARP1 or EC 2.4.2.30) targeted therapeutics, complete with analysis by indications, stage of development, mechanism of action (MoA), route of administration (RoA) and molecule type.

Poly [ADP Ribose] Polymerase 1 (ADP Ribosyltransferase Diphtheria Toxin Like 1 or NAD(+) ADP Ribosyltransferase 1 or Poly[ADP Ribose] Synthase 1 or PARP1 or EC 2.4.2.30) - Poly [ADP-ribose] polymerase 1 (PARP-1) is an enzyme encoded by the PARP1 gene. It is involved in the base excision repair (BER) pathway, by catalyzing the poly (ADP-ribosylation) of a limited number of acceptor proteins involved in chromatin architecture and in DNA metabolism. It positively regulates the transcription of MTUS1 and negatively regulates the transcription of MTUS2/TIP150. It is required for PARP9 and DTX3L recruitment to DNA damage sites. PARP1-dependent PARP9-DTX3L-mediated ubiquitination promotes the rapid and specific recruitment of 53BP1/TP53BP1, UIMC1/RAP80, and BRCA1 to DNA damage sites.  The molecules developed by companies in Pre-Registration, Phase III, Phase II, Phase I, IND/CTA Filed, Preclinical and Discovery stages are 3, 1, 5, 9, 1, 5 and 3 respectively. Similarly, the universities portfolio in Preclinical and Discovery stages comprises 3 and 1 molecules, respectively. Report covers products from therapy areas Oncology, Central Nervous System, Cardiovascular, Immunology, Respiratory, Toxicology and Undisclosed which include indications Breast Cancer, Ovarian Cancer, Solid Tumor, Fallopian Tube Cancer, Metastatic Breast Cancer, Peritoneal Cancer, Small-Cell Lung Cancer, Gastric Cancer, Metastatic Hormone Refractory (Castration Resistant, Androgen-Independent) Prostate Cancer, Diffuse Large B-Cell Lymphoma, Epithelial Ovarian Cancer, Metastatic Pancreatic Cancer, Bile Duct Cancer (Cholangiocarcinoma), Glioblastoma Multiforme (GBM), Malignant Mesothelioma, Mantle Cell Lymphoma, Melanoma, Non-Hodgkin Lymphoma, Non-Small Cell Lung Cancer, Pancreatic Cancer, Prostate Cancer, Acute Ischemic Stroke, Acute Myelocytic Leukemia (AML, Acute Myeloblastic Leukemia), Adenocarcinoma Of The Gastroesophageal Junction, B-Cell Chronic Lymphocytic Leukemia, Chronic Myelocytic Leukemia (CML, Chronic Myeloid Leukemia), Endometrial Cancer, Esophageal Cancer, Essential Thrombocythemia, Ewing Sarcoma, Follicular Lymphoma, Glioma, Head And Neck Cancer Squamous Cell Carcinoma, Hodgkin Lymphoma (B-Cell Hodgkin Lymphoma), Laryngeal Cancer, Leiomyosarcoma, Liver Cancer, Lung Cancer, Lung Injury, Lung Transplant Rejection, Marginal Zone B-cell Lymphoma, Metastatic Colorectal Cancer, Metastatic Melanoma, Metastatic Ovarian Cancer, Metastatic Prostate Cancer, Myelofibrosis, Neuroblastoma, Neuroendocrine Tumors, Organophosphate and Carbamate Poisoning, Oropharyngeal Cancer, Pancreatic Ductal Adenocarcinoma, Parkinson's Disease, Peritoneal Tumor, Polycythemia Vera, Rectal Cancer, Recurrent Glioblastoma Multiforme (GBM), Refractory Acute Myeloid Leukemia, Relapsed Acute Myeloid Leukemia, Renal Cell Carcinoma, Soft Tissue Sarcoma, Testicular Cancer, Traumatic Brain Injury, Unspecified and Uveal Melanoma. 

Furthermore, this report also reviews key players involved in Poly [ADP Ribose] Polymerase 1 (ADP Ribosyltransferase Diphtheria Toxin Like 1 or NAD(+) ADP Ribosyltransferase 1 or Poly[ADP Ribose] Synthase 1 or PARP1 or EC 2.4.2.30) targeted therapeutics development with respective active and dormant or discontinued projects. Driven by data and information sourced from proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources.

Note: Certain content / sections in the pipeline guide may be removed or altered based on the availability and relevance of data.

Scope

- The report provides a snapshot of the global therapeutic landscape for Poly [ADP Ribose] Polymerase 1 (ADP Ribosyltransferase Diphtheria Toxin Like 1 or NAD(+) ADP Ribosyltransferase 1 or Poly[ADP Ribose] Synthase 1 or PARP1 or EC 2.4.2.30)
- The report reviews Poly [ADP Ribose] Polymerase 1 (ADP Ribosyltransferase Diphtheria Toxin Like 1 or NAD(+) ADP Ribosyltransferase 1 or Poly[ADP Ribose] Synthase 1 or PARP1 or EC 2.4.2.30) targeted therapeutics under development by companies and universities/research institutes based on information derived from company and industry-specific sources 
- The report covers pipeline products based on various stages of development ranging from pre-registration till discovery and undisclosed stages 
- The report features descriptive drug profiles for the pipeline products which includes, product description, descriptive MoA, R&D brief, licensing and collaboration details & other developmental activities 
- The report reviews key players involved in Poly [ADP Ribose] Polymerase 1 (ADP Ribosyltransferase Diphtheria Toxin Like 1 or NAD(+) ADP Ribosyltransferase 1 or Poly[ADP Ribose] Synthase 1 or PARP1 or EC 2.4.2.30) targeted therapeutics and enlists all their major and minor projects 
- The report assesses Poly [ADP Ribose] Polymerase 1 (ADP Ribosyltransferase Diphtheria Toxin Like 1 or NAD(+) ADP Ribosyltransferase 1 or Poly[ADP Ribose] Synthase 1 or PARP1 or EC 2.4.2.30) targeted therapeutics based on mechanism of action (MoA), route of administration (RoA) and molecule type 
- The report summarizes all the dormant and discontinued pipeline projects 
- The report reviews latest news and deals related to Poly [ADP Ribose] Polymerase 1 (ADP Ribosyltransferase Diphtheria Toxin Like 1 or NAD(+) ADP Ribosyltransferase 1 or Poly[ADP Ribose] Synthase 1 or PARP1 or EC 2.4.2.30) targeted therapeutics

Reasons To Buy

- Gain strategically significant competitor information, analysis, and insights to formulate effective R&D strategies
- Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage 
- Identify and understand the targeted therapy areas and indications for Poly [ADP Ribose] Polymerase 1 (ADP Ribosyltransferase Diphtheria Toxin Like 1 or NAD(+) ADP Ribosyltransferase 1 or Poly[ADP Ribose] Synthase 1 or PARP1 or EC 2.4.2.30)
- Identify the use of drugs for target identification and drug repurposing
- Identify potential new clients or partners in the target demographic
- Develop strategic initiatives by understanding the focus areas of leading companies 
- Plan mergers and acquisitions effectively by identifying key players and it's most promising pipeline therapeutics
- Devise corrective measures for pipeline projects by understanding Poly [ADP Ribose] Polymerase 1 (ADP Ribosyltransferase Diphtheria Toxin Like 1 or NAD(+) ADP Ribosyltransferase 1 or Poly[ADP Ribose] Synthase 1 or PARP1 or EC 2.4.2.30) development landscape 
- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope.

 Table of Contents

Table of Contents 2
List of Tables 6
List of Figures 7
Introduction 8
Global Markets Direct Report Coverage 8
Poly [ADP Ribose] Polymerase 1 (ADP Ribosyltransferase Diphtheria Toxin Like 1 or NAD(+) ADP Ribosyltransferase 1 or Poly[ADP Ribose] Synthase 1 or PARP1 or EC 2.4.2.30) - Overview 9
Poly [ADP Ribose] Polymerase 1 (ADP Ribosyltransferase Diphtheria Toxin Like 1 or NAD(+) ADP Ribosyltransferase 1 or Poly[ADP Ribose] Synthase 1 or PARP1 or EC 2.4.2.30) - Therapeutics Development 10
Products under Development by Stage of Development 10
Products under Development by Therapy Area 11
Products under Development by Indication 12
Products under Development by Companies 17
Products under Development by Universities/Institutes 26
Poly [ADP Ribose] Polymerase 1 (ADP Ribosyltransferase Diphtheria Toxin Like 1 or NAD(+) ADP Ribosyltransferase 1 or Poly[ADP Ribose] Synthase 1 or PARP1 or EC 2.4.2.30) - Therapeutics Assessment 28
Assessment by Mechanism of Action 28
Assessment by Route of Administration 29
Assessment by Molecule Type 31
Poly [ADP Ribose] Polymerase 1 (ADP Ribosyltransferase Diphtheria Toxin Like 1 or NAD(+) ADP Ribosyltransferase 1 or Poly[ADP Ribose] Synthase 1 or PARP1 or EC 2.4.2.30) - Companies Involved in Therapeutics Development 33
AbbVie Inc 33
American Gene Technologies International Inc 34
AstraZeneca Plc 35
BeiGene Ltd 37
Checkpoint Therapeutics Inc 38
Clovis Oncology Inc 38
Hager Biosciences LLC 39
Ildong Pharmaceutical Co Ltd 39
IMPACT Therapeutics Inc 40
Jeil Pharmaceutical Co Ltd 40
Jiangsu Hengrui Medicine Co Ltd 41
Mitsubishi Tanabe Pharma Corp 41
Nerviano Medical Sciences Srl 42
Shanghai Acebright Pharmaceuticals Group Co Ltd 42
Tasly Pharmaceutical Group Co Ltd 43
Tesaro Inc 43
Teva Pharmaceutical Industries Ltd 44
Poly [ADP Ribose] Polymerase 1 (ADP Ribosyltransferase Diphtheria Toxin Like 1 or NAD(+) ADP Ribosyltransferase 1 or Poly[ADP Ribose] Synthase 1 or PARP1 or EC 2.4.2.30) - Drug Profiles 45
2X-121 - Drug Profile 45
Product Description 45
Mechanism Of Action 45
R&D Progress 45
ABT-767 - Drug Profile 47
Product Description 47
Mechanism Of Action 47
R&D Progress 47
AG-PD - Drug Profile 48
Product Description 48
Mechanism Of Action 48
R&D Progress 48
AZ-0108 - Drug Profile 49
Product Description 49
Mechanism Of Action 49
R&D Progress 49
AZD-1775 + olaparib - Drug Profile 50
Product Description 50
Mechanism Of Action 50
R&D Progress 50
AZD-6738 + olaparib - Drug Profile 51
Product Description 51
Mechanism Of Action 51
R&D Progress 51
BGB-290 - Drug Profile 52
Product Description 52
Mechanism Of Action 52
R&D Progress 52
BGBA-317 + BGB-290 - Drug Profile 55
Product Description 55
Mechanism Of Action 55
R&D Progress 55
cediranib maleate + olaparib - Drug Profile 57
Product Description 57
Mechanism Of Action 57
R&D Progress 57
CK-102 - Drug Profile 58
Product Description 58
Mechanism Of Action 58
R&D Progress 58
IMP-4297 - Drug Profile 59
Product Description 59
Mechanism Of Action 59
R&D Progress 59
JPI-289 - Drug Profile 61
Product Description 61
Mechanism Of Action 61
R&D Progress 61
MP-124 - Drug Profile 63
Product Description 63
Mechanism Of Action 63
R&D Progress 63
niraparib - Drug Profile 64
Product Description 64
Mechanism Of Action 64
R&D Progress 64
NMSP-118 - Drug Profile 73
Product Description 73
Mechanism Of Action 73
R&D Progress 73
NMSP-293 - Drug Profile 74
Product Description 74
Mechanism Of Action 74
R&D Progress 74
NOV-1401 - Drug Profile 75
Product Description 75
Mechanism Of Action 75
R&D Progress 75
olaparib - Drug Profile 76
Product Description 76
Mechanism Of Action 76
R&D Progress 76
R-554 - Drug Profile 89
Product Description 89
Mechanism Of Action 89
R&D Progress 89
rucaparib camsylate - Drug Profile 90
Product Description 90
Mechanism Of Action 90
R&D Progress 90
SC-10914 - Drug Profile 101
Product Description 101
Mechanism Of Action 101
R&D Progress 101
SHR-3162 - Drug Profile 102
Product Description 102
Mechanism Of Action 102
R&D Progress 102
Small Molecule to Inhibit PARP-1 and Activate AChE for Organophosphates Poisoning - Drug Profile 103
Product Description 103
Mechanism Of Action 103
R&D Progress 103
Small Molecule to Inhibit PARP-1 for Unspecified Indication - Drug Profile 104
Product Description 104
Mechanism Of Action 104
R&D Progress 104
Small Molecules to Inhibit PARP1 for Oncology - Drug Profile 105
Product Description 105
Mechanism Of Action 105
R&D Progress 105
Small Molecules to Target PARP1, 2, 3 and NO for Oncology - Drug Profile 106
Product Description 106
Mechanism Of Action 106
R&D Progress 106
SOMCL-9112 - Drug Profile 107
Product Description 107
Mechanism Of Action 107
R&D Progress 107
TSL-1502 - Drug Profile 108
Product Description 108
Mechanism Of Action 108
R&D Progress 108
veliparib ER - Drug Profile 109
Product Description 109
Mechanism Of Action 109
R&D Progress 109
XZ-120312 - Drug Profile 118
Product Description 118
Mechanism Of Action 118
R&D Progress 118
YHP-743 - Drug Profile 119
Product Description 119
Mechanism Of Action 119
R&D Progress 119
Poly [ADP Ribose] Polymerase 1 (ADP Ribosyltransferase Diphtheria Toxin Like 1 or NAD(+) ADP Ribosyltransferase 1 or Poly[ADP Ribose] Synthase 1 or PARP1 or EC 2.4.2.30) - Dormant Products 120
Poly [ADP Ribose] Polymerase 1 (ADP Ribosyltransferase Diphtheria Toxin Like 1 or NAD(+) ADP Ribosyltransferase 1 or Poly[ADP Ribose] Synthase 1 or PARP1 or EC 2.4.2.30) - Discontinued Products 123
Poly [ADP Ribose] Polymerase 1 (ADP Ribosyltransferase Diphtheria Toxin Like 1 or NAD(+) ADP Ribosyltransferase 1 or Poly[ADP Ribose] Synthase 1 or PARP1 or EC 2.4.2.30) - Product Development Milestones 124
Featured News & Press Releases 124
Sep 21, 2017: First-in-class BRCA-positive Ovarian Cancer Medicine Lynparza (olaparib) Receives Positive pan-Canadian Oncology Drug Review (pCODR) Recommendation for Provincial Reimbursement 124
Sep 15, 2017: TESARO Receives Positive CHMP Opinion for ZEJULA 124
Sep 13, 2017: Clovis Oncology's Rucaparib ARIEL3 Study Data Published in The Lancet 125
Sep 11, 2017: TESARO Summarizes ZEJULA Data Presented at 2017 ESMO Annual Meeting 126
Sep 08, 2017: BeiGene Presents Preliminary Phase 1/2 Clinical Data on PARP Inhibitor BGB-290 in Patients with Advanced Solid Tumors at the European Society for Medical Oncology 2017 Congress 129
Sep 07, 2017: Clovis Oncology Presents Comprehensive Dataset from Successful Phase 3 ARIEL3 Maintenance Treatment Trial of Rucaparib in Advanced Ovarian Cancer at ESMO 2017 130
Aug 30, 2017: Clovis Oncology to Present Comprehensive Dataset from Successful ARIEL3 Clinical Trial Program at 2017 ESMO Congress 133
Aug 30, 2017: BeiGene Announces Presentations on its PARP inhibitor BGB-290 at the European Society for Medical Oncology 2017 Congress 134
Aug 25, 2017: TESARO Announces Eight Poster Presentations on ZEJULA at the 2017 European Society for Medical Oncology (ESMO) Annual Meeting 134
Aug 17, 2017: FDA approves olaparib tablets for maintenance treatment in ovarian cancer 136
Aug 09, 2017: 2X Oncology Announces Validation of Drug Response Predictor for its PARP Inhibitor 2X-121 136
Aug 01, 2017: Successful DRP prediction of patients treated with 2X-121, the PARP inhibitor recently licensed from Eisai 137
Jul 24, 2017: STA Signs Supply Agreement with TESARO 138
Jun 19, 2017: Clovis Oncology's Rucaparib Significantly Improved Progression-Free Survival In All Ovarian Cancer Patient Populations Studied In Phase 3 ARIEL3 Maintenance Treatment Trial 139
Jun 05, 2017: BeiGene Presents Initial Phase 1 Data on Anti-PD-1 Antibody BGB-A317 Combined with PARP Inhibitor BGB-290 at the 2017 American Society for Clinical Oncology Annual Meeting 142
Appendix 144
Methodology 144
Coverage 144
Secondary Research 144
Primary Research 144
Expert Panel Validation 144
Contact Us 144
Disclaimer 145

List of Tables

Number of Products under Development by Stage of Development, H2 2017 10
Number of Products under Development by Therapy Areas, H2 2017 11
Number of Products under Development by Indications, H2 2017 12
Number of Products under Development by Indications, H2 2017 (Contd..1), H2 2017 14
Number of Products under Development by Indications, H2 2017 (Contd..2), H2 2017 15
Number of Products under Development by Indications, H2 2017 (Contd..3), H2 2017 16
Number of Products under Development by Companies, H2 2017 17
Products under Development by Companies, H2 2017 18
Products under Development by Companies, H2 2017 (Contd..1), H2 2017 19
Products under Development by Companies, H2 2017 (Contd..2), H2 2017 20
Products under Development by Companies, H2 2017 (Contd..3), H2 2017 21
Products under Development by Companies, H2 2017 (Contd..4), H2 2017 22
Products under Development by Companies, H2 2017 (Contd..5), H2 2017 23
Products under Development by Companies, H2 2017 (Contd..6), H2 2017 24
Products under Development by Companies, H2 2017 (Contd..7), H2 2017 25
Number of Products under Investigation by Universities/Institutes, H2 2017 26
Products under Investigation by Universities/Institutes, H2 2017 27
Number of Products by Stage and Mechanism of Actions, H2 2017 28
Number of Products by Stage and Route of Administration, H2 2017 30
Number of Products by Stage and Molecule Type, H2 2017 32
Pipeline by AbbVie Inc, H2 2017 34
Pipeline by American Gene Technologies International Inc, H2 2017 34
Pipeline by AstraZeneca Plc, H2 2017 36
Pipeline by BeiGene Ltd, H2 2017 37
Pipeline by Checkpoint Therapeutics Inc, H2 2017 38
Pipeline by Clovis Oncology Inc, H2 2017 39
Pipeline by Hager Biosciences LLC, H2 2017 39
Pipeline by Ildong Pharmaceutical Co Ltd, H2 2017 40
Pipeline by IMPACT Therapeutics Inc, H2 2017 40
Pipeline by Jeil Pharmaceutical Co Ltd, H2 2017 41
Pipeline by Jiangsu Hengrui Medicine Co Ltd, H2 2017 41
Pipeline by Mitsubishi Tanabe Pharma Corp, H2 2017 42
Pipeline by Nerviano Medical Sciences Srl, H2 2017 42
Pipeline by Shanghai Acebright Pharmaceuticals Group Co Ltd, H2 2017 42
Pipeline by Tasly Pharmaceutical Group Co Ltd, H2 2017 43
Pipeline by Tesaro Inc, H2 2017 44
Pipeline by Teva Pharmaceutical Industries Ltd, H2 2017 44
Dormant Products, H2 2017 120
Dormant Products, H2 2017 (Contd..1), H2 2017 121
Dormant Products, H2 2017 (Contd..2), H2 2017 122
Discontinued Products, H2 2017 123